company background image
TMBR.Q logo

Timber Pharmaceuticals OTCPK:TMBR.Q Stock Report

Last Price

US$0.0002

Market Cap

US$308.0

7D

100.0%

1Y

-100.0%

Updated

28 Mar, 2024

Data

Company Financials

Timber Pharmaceuticals, Inc.

OTCPK:TMBR.Q Stock Report

Market Cap: US$308.0

TMBR.Q Stock Overview

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases.

TMBR.Q fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Timber Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Timber Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.0002
52 Week HighUS$3.36
52 Week LowUS$0.0001
Beta-1.48
1 Month Change-83.33%
3 Month Change-83.33%
1 Year Change-99.99%
3 Year Change-100.00%
5 Year Changen/a
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

TMBR.QUS PharmaceuticalsUS Market
7D100.0%1.2%0.4%
1Y-100.0%25.8%28.8%

Return vs Industry: TMBR.Q underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: TMBR.Q underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is TMBR.Q's price volatile compared to industry and market?
TMBR.Q volatility
TMBR.Q Average Weekly Movement147.9%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TMBR.Q's share price has been volatile over the past 3 months.

Volatility Over Time: TMBR.Q's weekly volatility has decreased from 644% to 148% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20199John Koconishttps://www.timberpharma.com

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company’s lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea.

Timber Pharmaceuticals, Inc. Fundamentals Summary

How do Timber Pharmaceuticals's earnings and revenue compare to its market cap?
TMBR.Q fundamental statistics
Market capUS$308.00
Earnings (TTM)-US$14.93m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TMBR.Q income statement (TTM)
RevenueUS$0
Cost of RevenueUS$8.73m
Gross Profit-US$8.73m
Other ExpensesUS$6.21m
Earnings-US$14.93m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.84
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TMBR.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.